home / stock / fdmt / fdmt articles

FDMT Articles, 4D Molecular Therapeutics Inc.

Stock Information
Company Name: 4D Molecular Therapeutics Inc.
Stock Symbol: FDMT
Market: NASDAQ
Menu
FDMT FDMT Quote FDMT Short FDMT News FDMT Articles FDMT Message Board
Get FDMT Alerts

News, Short Squeeze, Breakout and More Instantly...
4DMT to Present Initial Interim 24-week Landmark Analysis from the 4D-150 Phase 2 PRISM Population Extension Cohort in a Broad Wet AMD Population at ASRS and Host a Corporate Webcast | Benzinga

24-week landmark safety and clinical activity data for 45 patients enrolled in the Population Extension cohort expected to be presented (N=30 at ...
4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting | Benzinga

Injection-free subgroup results demonstrated that a single intravitreal dose of 4D-150 without any supplemental anti-VEGF injections resulted in ...

Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside | Benzinga

Goldman Sachs has initiated coverage on Regenxbio Inc (NASDAQ:RGNX), citing the potential for the company’s gene therapy platform. The compan...

Why G-III Apparel Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session | Benzinga

Shares of G-III Apparel Group, Ltd. (NASDAQ:GIII) fell sharply during Thursday's session after the company reported worse-than-expected quarte...
Why Is 4D Molecular Therapeutics Stock Trading Lower On Thursday? Genetic Disease-Focused Study Data Released | Benzinga

4D Molecular Therapeutics (NASDAQ:FDMT) released data from a clinical trial for cystic fibrosis lung disease. What Happened: The company unveiled ...

4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Modulator-Ineligible/-Intolerant Cystic Fibrosis at 47th European Cystic Fibrosis Conference | Benzinga

Clinically meaningful improvements in ppFEV1 at 12 months observed in 2 of 3 participants with mild to moderate baseline lung function impairment...

4DMT Announces Presentations at Clinical Trials at the Summit 2024 Meeting | Benzinga

EMERYVILLE, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading clinical-stage ge...
4D Molecular Therapeutics Outlines Pivotal Development Plans For Cystic Fibrosis, Rare Inherited Disease | Benzinga

4D Molecular Therapeutics Inc (NASDAQ:FDMT) announced an update on its 4D-710, an aerosolized genetic medicine for cystic fibrosis (CF) l...

Why Is Blindness Focused-Adverum Biotechnologies Stock Trading Lower Today? | Benzinga

Adverum Biotechnologies Inc (NASDAQ:ADVM) released preliminary safety and efficacy data from the ongoing LUNA Phase 2 trial in patients with w...

Why 4D Molecular Therapeutics (FDMT) Stock Is Diving | Benzinga

4D Molecular Therapeutics Inc (NASDAQ:FDMT) shares are trading lower by 11.7% to $28.33 Wednesday afternoon after the company announced an upsized ...
Next 10